Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc. is a commercial-stage clinical biopharmaceutical company. The Company is focused on the development and commercialization of novel, antibody based therapeutic products for the treatment of cancer. Its product pipeline includes DANYELZA (naxitamab-gqgk), which is a humanized monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor, or GM-CSF,for the treatment of in the bone or bone marrow stable disease to prior therapy and being evaluated for the treatment of other GD2-positive tumors. It also develops Omburtamab, which is novel murine monoclonal antibody targeting B7-H3. The Company is conducting Phase II clinical trials for the treatment of patients with first-line NB, third-line NB, and in relapsed osteosarcoma.

Number of employees : 125 people.
Sales per Business
20192020Delta
Novel Antibody-based Therapeutic Products--20.75100%-
USD in Million
Sales per region
20192020Delta
United States--20.75100%-
USD in Million
Managers
Name Title Age Since
Claus Juan M°ller-San Pedro, Dr. Chief Executive Officer & Director 58 2015
Thomas Gad Chairman, President & Head-Business Development 50 2015
Bo Kruse CFO, Secretary. Treasurer & Executive VP 48 2019
Torben Lund-Hansen, Dr. Chief Technology Officer & Senior Vice President 69 2016
Steen Lisby, Dr. Chief Scientific Officer & Senior Vice President 56 -
Vignesh Rajah Chief Medical Officer & Senior Vice President - -
Joris Wiel Jan Wilms Chief Operating Officer & Senior Vice President 46 2017
Johan Ernst Wedell-Wedellsborg Independent Director 50 2015
Ashutosh Tyagi, Dr. Independent Director 44 2017
James Irvin Healy, Dr. Independent Director 55 2017
Members of the board
Name Title Age Since
Thomas Gad Chairman, President & Head-Business Development 50 2015
Claus Juan M°ller-San Pedro, Dr. Chief Executive Officer & Director 58 2015
Johan Ernst Wedell-Wedellsborg Independent Director 50 2015
Ashutosh Tyagi, Dr. Independent Director 44 2017
James Irvin Healy, Dr. Independent Director 55 2017
David Neil Gill Independent Director 65 2017
GÚrard Ber, Dr. Independent Director 62 2018
Laura J. Hamill Independent Director 55 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 43,576,950 36,460,029 83.7% 0 0.0% 83.7%
Shareholders
NameEquities%
Wellington Management Co. LLP 4,448,610 10.2%
Johan Ernst Wedell-Wedellsborg 4,017,236 9.22%
Sofinnova Investments, Inc. 2,194,278 5.04%
HBM Partners AG (Investment Management) 2,130,373 4.89%
Fidelity Management & Research Co. LLC 1,548,987 3.55%
Thomas Gad 1,546,927 3.55%
The Vanguard Group, Inc. 1,545,011 3.55%
SSgA Funds Management, Inc. 1,389,511 3.19%
AllianceBernstein LP 1,348,596 3.09%
Artisan Partners LP 1,318,279 3.03%
Company contact information
Y-mAbs Therapeutics, Inc.
230 Park Avenue
Suite 3350
New York, NY 10169

Phone : +1.646.885.8505
Web : http://www.ymabs.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Y-mAbs Therapeutics, Inc.
Sector Bio Therapeutic Drugs